У нас вы можете посмотреть бесплатно Brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical Hodgkin lymphoma или скачать в максимальном доступном качестве, которое было загружено на ютуб. Для скачивания выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Jeremy Abramson, MD, Massachusetts General Hospital, Boston, MA, discusses the results of a Phase II trial (NCT02505269) assessing brentuximab vedotin (BV) in combination with doxorubicin and dacarbazine (AD) for the treatment of limited-stage classical Hodgkin lymphoma (cHL). BV-AD was associated with excellent complete response (CR) and progression-free survival (PFS) rates, and a reduced toxicity profile. Dr Abramson also highlights an ongoing Phase II trial (NCT03646123) assessing the addition of nivolumab to this treatment regimen in limited-stage HL, which has reported a benefit with respect to CR and PFS rates in interim analyses. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.